# Safety and Pharmacokinetics of a Single Dose of CCH (3.36 mg) in Subjects With EFP

> **NCT03675685** · PHASE1 · COMPLETED · sponsor: **Endo Pharmaceuticals** · enrollment: 12 (actual)

## Conditions studied

- Edematous Fibrosclerotic Panniculopathy

## Interventions

- **BIOLOGICAL:** CCH (collagenase clostridium histolyticum)

## Key facts

- **NCT ID:** NCT03675685
- **Lead sponsor:** Endo Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-18
- **Primary completion:** 2018-11-01
- **Final completion:** 2018-11-01
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2020-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03675685

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03675685, "Safety and Pharmacokinetics of a Single Dose of CCH (3.36 mg) in Subjects With EFP". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03675685. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*